Compare Entergy Corporation (ETR) vs Moderna, Inc. (MRNA) Price & Performance

Entergy (ETR) trades at $109.87, down 0.22% on the day, with strong technical momentum showing bullish moving averages and key support at $109. The company delivered three consecutive earnings beats in 2026, including Q3 EPS of $1.98 beating estimates by 14.5%, while recently raising its dividend 6.3% to $0.68 per share. Revenue growth continues with 2026 guidance showing $13.5B in projected revenue, supported by increased electricity demand and regulatory rate actions.

Wall Street maintains strong bullish sentiment with 59% buy ratings and a $119.81 consensus target offering 9% upside potential. Key risks include high capital expenditure requirements exceeding operational cash flow and potential regulatory headwinds. The stock presents a compelling opportunity for dividend growth investors seeking defensive exposure amid market volatility.

Moderna (MRNA) trades at $220.83, down 0.4% on the day but maintaining a strong 2026 rally of over 500%. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to post revenue declines and significant net losses, with 2025 revenue at $1.92B and net loss of $2.82B. Recent catalyst includes Nasdaq-100 inclusion effective October 9, 2026, which may drive additional institutional demand.

Outlook remains bifurcated between technical momentum and fundamental challenges. The Nasdaq-100 inclusion and cancer vaccine pipeline offer growth potential, but persistent losses and valuation concerns create headwinds. Current price sits near consensus target of $132.70, suggesting limited upside from analyst perspective despite recent rally momentum.